Compare Stocks → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATNFNASDAQ:CBIONASDAQ:CLRBNASDAQ:ONTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNF180 Life Sciences$1.80+1.7%$2.82$1.33▼$27.93$1.51M0.44105,472 shs20,409 shsCBIOCatalyst Biosciences$0.77$0.19▼$8.69$291.29M1.05763,526 shs32,246 shsCLRBCellectar Biosciences$3.03+0.3%$3.63$1.33▼$4.45$97.75M0.921.64 million shs686,577 shsONTXOnconova Therapeutics$0.84$0.55▼$1.45$20.90M1.3896,681 shs1.28 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNF180 Life Sciences-2.81%-3.34%-10.67%-59.20%-91.30%CBIOCatalyst Biosciences0.00%0.00%0.00%0.00%+3,234.57%CLRBCellectar Biosciences-1.31%-0.66%-21.56%-19.47%+106.71%ONTXOnconova Therapeutics0.00%0.00%+10.59%+40.84%-5.21%The Next Step of Their Control Is Here … (Ad)Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNF180 Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ACBIOCatalyst BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACLRBCellectar Biosciences2.2136 of 5 stars3.54.00.00.02.50.00.6ONTXOnconova Therapeutics0.7669 of 5 stars3.53.00.00.00.00.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNF180 Life SciencesN/AN/AN/AN/ACBIOCatalyst BiosciencesN/AN/AN/AN/ACLRBCellectar Biosciences3.00Buy$20.00560.07% UpsideONTXOnconova Therapeutics3.00Buy$11.00∞ UpsideCurrent Analyst RatingsLatest CLRB, CBIO, ONTX, and ATNF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024CLRBCellectar BiosciencesRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $28.003/28/2024CLRBCellectar BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $12.003/4/2024CLRBCellectar BiosciencesRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNF180 Life SciencesN/AN/AN/AN/A($0.24) per shareN/ACBIOCatalyst Biosciences$790K0.00N/AN/A($0.78) per share0.00CLRBCellectar BiosciencesN/AN/AN/AN/A($0.36) per shareN/AONTXOnconova Therapeutics$230K0.00N/AN/A$1.35 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNF180 Life Sciences-$19.93MN/A0.00∞N/AN/A-320.26%-112.07%5/20/2024 (Estimated)CBIOCatalyst Biosciences-$8.24M-$1.38N/AN/AN/AN/A-364.68%-281.68%N/ACLRBCellectar Biosciences-$37.98M-$3.10N/AN/AN/AN/A-3,821.29%-280.23%5/2/2024 (Estimated)ONTXOnconova Therapeutics-$18.96M-$0.91N/AN/AN/A-8,930.97%-95.43%-61.19%5/20/2024 (Estimated)Latest CLRB, CBIO, ONTX, and ATNF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023CLRBCellectar Biosciences-$0.59-$0.66-$0.07-$0.92N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNF180 Life SciencesN/AN/AN/AN/AN/ACBIOCatalyst BiosciencesN/AN/AN/AN/AN/ACLRBCellectar BiosciencesN/AN/AN/AN/AN/AONTXOnconova TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNF180 Life SciencesN/A0.720.72CBIOCatalyst BiosciencesN/A2.882.88CLRBCellectar BiosciencesN/A0.810.81ONTXOnconova TherapeuticsN/A2.792.79OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNF180 Life Sciences4.07%CBIOCatalyst Biosciences5.98%CLRBCellectar Biosciences16.41%ONTXOnconova Therapeutics7.95%Insider OwnershipCompanyInsider OwnershipATNF180 Life Sciences4.10%CBIOCatalyst Biosciences2.92%CLRBCellectar Biosciences4.60%ONTXOnconova Therapeutics3.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATNF180 Life Sciences4853,000818,000No DataCBIOCatalyst Biosciences737.98 million36.87 millionOptionableCLRBCellectar Biosciences2032.26 million30.78 millionOptionableONTXOnconova Therapeutics1621.00 million20.31 millionOptionableCLRB, CBIO, ONTX, and ATNF HeadlinesSourceHeadlineOnconova Therapeutics (NASDAQ:ONTX) Now Covered by StockNews.comamericanbankingnews.com - April 24 at 2:22 AMOnconova Therapeutics (NASDAQ:ONTX) Coverage Initiated at StockNews.comamericanbankingnews.com - April 16 at 2:22 AMOnconova and Trawsfynydd merge to form Traws Pharmauk.investing.com - April 4 at 6:50 PMTraws Pharma Full Year 2023 Earnings: Beats Expectationsfinance.yahoo.com - April 4 at 6:50 PMNewtown’s Onconova Therapeutics Secures $14 Million and New CEO in Merger with Trawsfynyddmsn.com - April 3 at 5:47 PMOnconova Acquires Trawsfynydd To Form Traws Pharmamarkets.businessinsider.com - April 2 at 10:00 AMTraws Pharma Announces New Employee Inducement Grantsglobenewswire.com - April 2 at 7:15 AMOnconova to Unveil New Rigosertib Study Results at Cancer Research Meetingmsn.com - March 12 at 8:48 AMAnalysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX) and Biogen (BIIB)markets.businessinsider.com - March 11 at 1:17 PMOnconova Therapeutics’ Rigosertib Poster Selected for AACR 2024finance.yahoo.com - March 8 at 9:56 AMOnconova Therapeutics' Rigosertib Poster Selected for AACR 2024globenewswire.com - March 8 at 8:00 AMOnconova Therapeutics Inc (ONTX)investing.com - February 13 at 12:22 AMOnconova Therapeutics, Inc. (ONTX)finance.yahoo.com - January 23 at 10:41 PMOnconova Therapeutics Stock (NASDAQ:ONTX) Dividends: History, Yield and Datesbenzinga.com - December 21 at 11:07 PMOnconova stock falls 10% on preclinical data for lymphoma drugmsn.com - December 12 at 4:02 PMOnconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphomafinance.yahoo.com - December 12 at 9:55 AMOnconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’sfinance.yahoo.com - December 8 at 6:47 PMOnconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conferencefinance.yahoo.com - November 28 at 10:06 AMOnconova Therapeutics, Inc. (NASDAQ:ONTX) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 16 at 12:48 PMOnconova Therapeutics, Inc.: Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Resultsfinanznachrichten.de - November 16 at 1:30 AMOnconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 14 at 6:28 PMOnconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023finance.yahoo.com - November 7 at 5:22 PMOnconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCLbenzinga.com - November 2 at 7:56 PMOnconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCLfinance.yahoo.com - November 2 at 2:55 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany Descriptions180 Life SciencesNASDAQ:ATNF180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.Catalyst BiosciencesNASDAQ:CBIOCatalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.Cellectar BiosciencesNASDAQ:CLRBCellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Onconova TherapeuticsNASDAQ:ONTXOnconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.